Results 11 to 20 of about 125,716 (297)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

Hepatology, 2023
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach.
Z. Younossi, P. Golabi, James M. Paik, Austin Henry, Catherine Van Dongen, L. Henry   +5 more
semanticscholar   +1 more source

Immune cell-mediated features of non-alcoholic steatohepatitis

Nature reviews. Immunology, 2021
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health
T. Huby, E. Gautier
semanticscholar   +1 more source

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

New England Journal of Medicine, 2020
BACKGROUND Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.
P. Newsome, Kristine Buchholtz, K. Cusi, Martin Linder, T. Okanoue, V. Ratziu, A. Sanyal, A. Sejling, S. Harrison   +8 more
semanticscholar   +1 more source

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

Nature Medicine, 2023
The FLIGHT-FXR trial, testing farnesoid X receptor agonist tropifexor in nonalcoholic steatohepatitis, demonstrated sustained decreases in alanine aminotransferase levels and hepatic fat fraction, but not aspartate aminotransferase, with dose-dependent ...
A. Sanyal, Patricia Lopez, E. Lawitz, K. Lucas, J. Loeffler, Won Kim, G. Goh, Jee‐Fu Huang, C. Serra, P. Andreone, Yi-Cheng Chen, S. Hsia, V. Ratziu, D. Aizenberg, Hiroshi Tobita, A. Sheikh, J. Vierling, Y. Kim, H. Hyogo, Dean Tai, Z. Goodman, F. Schaefer, I. R. Carbarns, S. Lamle, M. Martic, N. Naoumov, C. Brass   +26 more
semanticscholar   +1 more source

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol

Nature Communications, 2023
The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis.
Ming Yang, Xiaoqiang Qi, Nan Li, J. Kaifi, Shiyou Chen, Andrew A. Wheeler, E. Kimchi, A. Ericsson, R. Scott Rector, K. Staveley-O’Carroll, Guangfu Li   +10 more
semanticscholar   +1 more source

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Clinical and Molecular Hepatology, 2022
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes lipid accumulation.
Kuei-Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin   +2 more
semanticscholar   +1 more source

Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation

Gastroenterology Insights, 2023
Hepatitis C infection is a leading etiology of hepatic dysfunction and a major indication for liver transplantation due to the development of fibrosis, cirrhosis, and hepatocellular carcinoma.
Sonia Samuel, Ahmad Abulawi, Raza Malik
doaj   +1 more source

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis

Frontiers in Cell and Developmental Biology, 2023
In recent years, there has been a rapid expansion in our understanding of regulated cell death, leading to the discovery of novel mechanisms that govern diverse cell death pathways.
Christian Stoess, Christian Stoess, Aleksandra Leszczynska, Lin Kui, Ariel E. Feldstein   +4 more
doaj   +1 more source

Non-alcoholic fatty liver disease: Definition and subtypes [PDF]

Clinical and Molecular Hepatology, 2023
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported depending on the comorbidities.
Seul Ki Han, Soon Koo Baik, Moon Young Kim   +2 more
doaj   +1 more source

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Hepatology, 2019
Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world.
Z. Younossi, F. Tacke, M. Arrese, Barjesh Chander Sharma, I. Mostafa, E. Bugianesi, V. Wai‐Sun Wong, Y. Yılmaz, J. George, Jian-Gao Fan, M. Vos   +10 more
semanticscholar   +1 more source